Corcept Investors Face April 21 Deadline to Seek Lead Role in Securities Class Action

Filings claim the company downplayed FDA objections to relacorilant by touting its approval prospects.

Overview

Rosen Law Firm, The Schall Law Firm, and DJS Law Group are soliciting shareholders who bought Corcept stock between October 31, 2024 and December 30, 2025.
The complaints assert violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.
Plaintiffs allege Corcept said relacorilant was “approaching approval” even as the FDA repeatedly questioned whether its clinical evidence was adequate.
Investors seeking to be appointed lead plaintiff must move the court by April 21, 2026.
No class has been certified, so investors are not represented unless they retain counsel, and serving as lead plaintiff is not required to share in any potential recovery.